Physician
Aurora Medical Center of Oshkosh, INC
Aurora Medical Center of Oshkosh, INC was paid $16.47M by Medicaid between Jan 2018 and Dec 2024, across 284 billing codes. Its largest line is 99283, emergency room visit (moderate) — 9.8% of everything it billed.
33Billing provider infoAURORA MEDICAL CENTER OF OSHKOSH, INC
OSHKOSH, WI 54904
OSHKOSH, WI 54904
33aNPI1275578064assigned 06/17/2006
33bProvider typeHematology & Oncology Physician
28Total paid$16.47M
24GClaims732,392
24DCodes billed284
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in Wisconsin
Rank by total paid#2 of 10
Median peer was paid$49K
This provider vs. median335×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,267 | $1.69M | |
| 2019 | 86,335 | $1.94M | |
| 2020 | 83,149 | $1.88M | |
| 2021 | 118,307 | $2.43M | |
| 2022 | 126,996 | $2.72M | |
| 2023 | 135,192 | $3.07M | |
| 2024incomplete | 105,146 | $2.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.8% | 27,177 | 23,975 | $1.61M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.3% | 11,965 | 9,234 | $1.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.1% | 32,703 | 28,977 | $1.50M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.4% | 39,696 | 15,966 | $1.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 17,973 | 16,002 | $880K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.8% | 21,510 | 9,101 | $457K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 7,118 | 6,397 | $452K |
| 80053 | Comprehensive metabolic panel | 2.7% | 26,474 | 19,996 | $451K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 4,716 | 4,252 | $368K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 3,624 | 2,735 | $303K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 4,034 | 3,606 | $300K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 4,631 | 3,177 | $297K |
272 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.6% | 4,921 | $265K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 11,363 | $264K |
| 64493 | 1.5% | 1,147 | $251K | |
| 97161 | 1.5% | 5,982 | $243K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 33,452 | $214K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 4,704 | $197K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 2,295 | $195K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,826 | $189K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 3,419 | $186K |
| 64494 | 1.1% | 1,459 | $185K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 2,284 | $173K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 840 | $172K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,981 | $156K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,071 | $144K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,558 | $132K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,197 | $130K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,590 | $126K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,470 | $116K |
| 83880 | <1% | 3,569 | $113K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,080 | $113K |
| 84484 | <1% | 9,929 | $108K | |
| 64635 | <1% | 563 | $94K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 585 | $90K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,401 | $81K |
| 64636 | <1% | 552 | $80K | |
| 97162 | <1% | 2,343 | $78K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,983 | $77K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,909 | $77K |
| 81025 | <1% | 6,872 | $70K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,078 | $70K |
| 82962 | <1% | 7,629 | $67K | |
| 73630 | <1% | 3,531 | $61K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,347 | $60K |
| 83690 | <1% | 10,089 | $60K | |
| 82077 | <1% | 2,704 | $58K | |
| 83735 | <1% | 11,015 | $58K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,038 | $57K |
| 93356 | <1% | 521 | $57K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,322 | $56K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 141 | $55K |
| 93975 | <1% | 1,351 | $54K | |
| 62323 | <1% | 336 | $53K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 808 | $49K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 430 | $49K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 846 | $46K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 213 | $43K |
| 97165 | <1% | 1,308 | $43K | |
| 97035 | <1% | 3,671 | $41K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,144 | $41K |
| 83605 | <1% | 4,188 | $40K | |
| 84145 | <1% | 2,032 | $40K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 379 | $40K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,843 | $39K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,161 | $39K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 949 | $39K |
| G0378 | Hospital observation service, per hour | <1% | 2,985 | $38K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 741 | $37K |
| 93971 | <1% | 1,241 | $36K | |
| 81001 | <1% | 9,451 | $36K | |
| 73610 | <1% | 2,229 | $35K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 519 | $35K |
| 76830 | Ultrasound, transvaginal | <1% | 1,131 | $34K |
| 84703 | <1% | 3,079 | $33K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,363 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,025 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,147 | $30K |
| 85379 | <1% | 3,480 | $28K | |
| 82803 | <1% | 1,341 | $26K | |
| 97116 | <1% | 2,176 | $26K | |
| 86140 | <1% | 4,652 | $23K | |
| 93017 | <1% | 746 | $23K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 307 | $23K |
| 74018 | <1% | 1,180 | $22K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,618 | $22K |
| 73030 | <1% | 1,777 | $21K | |
| 87040 | <1% | 1,690 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,647 | $20K |
| 87081 | <1% | 427 | $19K | |
| 73110 | <1% | 1,111 | $18K | |
| 81003 | <1% | 4,176 | $18K | |
| 80047 | <1% | 547 | $18K | |
| 73130 | <1% | 1,452 | $17K | |
| 86850 | <1% | 949 | $17K | |
| 85610 | <1% | 4,563 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 359 | $17K |
| 72100 | <1% | 1,379 | $16K | |
| 96367 | <1% | 281 | $15K | |
| 0240U | <1% | 487 | $15K | |
| 76536 | <1% | 401 | $14K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 47 | $14K |
| 71250 | <1% | 511 | $14K | |
| 80143 | <1% | 1,225 | $14K | |
| 87077 | <1% | 977 | $14K | |
| 82330 | <1% | 1,133 | $14K | |
| 80179 | <1% | 1,191 | $13K | |
| 70498 | <1% | 149 | $13K | |
| 73564 | <1% | 1,025 | $13K | |
| 84702 | <1% | 786 | $13K | |
| 85730 | <1% | 2,743 | $12K | |
| 95886 | <1% | 240 | $12K | |
| 72141 | <1% | 174 | $12K | |
| 94729 | <1% | 663 | $11K | |
| 87210 | <1% | 1,221 | $11K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 310 | $10K |
| 76642 | <1% | 293 | $10K | |
| 87186 | <1% | 1,296 | $10K | |
| 63650 | <1% | 34 | $10K | |
| 85027 | <1% | 1,698 | $9K | |
| 73562 | <1% | 853 | $9K | |
| 94726 | <1% | 625 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,748 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 495 | $8K |
| 87070 | <1% | 616 | $8K | |
| 70496 | <1% | 67 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 447 | $7K |
| 97166 | <1% | 224 | $7K | |
| 73502 | <1% | 692 | $7K | |
| 73140 | <1% | 410 | $7K | |
| 97597 | <1% | 240 | $7K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,401 | $7K |
| 74019 | <1% | 228 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 41 | $6K |
| 12001 | <1% | 84 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 82 | $6K |
| 84132 | <1% | 1,184 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,260 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,012 | $5K |
| 93308 | <1% | 40 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,307 | $5K |
| 76770 | <1% | 79 | $5K | |
| 27096 | <1% | 26 | $4K | |
| 86900 | <1% | 1,164 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,538 | $4K |
| 80076 | <1% | 558 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,717 | $4K |
| 85652 | <1% | 1,741 | $4K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 90 | $3K |
| 82728 | <1% | 326 | $3K | |
| 29581 | <1% | 48 | $3K | |
| 86901 | <1% | 1,161 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 300 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,995 | $2K |
| 73080 | <1% | 211 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,572 | $2K |
| 94060 | <1% | 73 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 26 | $2K |
| 87205 | <1% | 798 | $2K | |
| 87088 | <1% | 307 | $2K | |
| 96415 | <1% | 32 | $2K | |
| 76801 | <1% | 79 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,422 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 237 | $2K |
| 70486 | <1% | 55 | $2K | |
| 77002 | <1% | 47 | $1K | |
| 90715 | <1% | 57 | $1K | |
| 93970 | <1% | 41 | $1K | |
| 93922 | <1% | 27 | $1K | |
| 82550 | <1% | 242 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 18 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,862 | $1K |
| 73660 | <1% | 75 | $1K | |
| 93880 | <1% | 25 | $1K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 26 | $1K |
| 87807 | <1% | 72 | $1K | |
| 83550 | <1% | 171 | $982.49 | |
| 87075 | <1% | 190 | $967.87 | |
| 71271 | <1% | 14 | $855.23 | |
| 71101 | <1% | 83 | $825.77 | |
| 95913 | <1% | 26 | $807.68 | |
| 20999 | <1% | 22 | $770.00 | |
| 83540 | <1% | 176 | $761.39 | |
| 73221 | <1% | 15 | $638.48 | |
| 72110 | <1% | 28 | $579.46 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,902 | $576.61 |
| 80061 | Lipid panel | <1% | 62 | $560.39 |
| 97760 | <1% | 28 | $534.08 | |
| 96376 | <1% | 3,640 | $500.35 | |
| 90686 | <1% | 40 | $495.44 | |
| 82150 | <1% | 75 | $493.74 | |
| 73590 | <1% | 55 | $420.07 | |
| 72146 | <1% | 12 | $409.06 | |
| 85014 | <1% | 234 | $391.91 | |
| 83615 | <1% | 96 | $319.72 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,562 | $315.80 |
| 94010 | <1% | 55 | $290.84 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 93 | $272.36 |
| 82607 | <1% | 26 | $239.94 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 234 | $202.00 |
| 82010 | <1% | 27 | $200.76 | |
| 72040 | <1% | 12 | $188.04 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,472 | $181.76 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 597 | $168.13 |
| 73560 | <1% | 15 | $158.25 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 143 | $158.07 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 960 | $156.15 |
| 82746 | <1% | 13 | $141.27 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,426 | $138.63 |
| 74022 | <1% | 73 | $136.50 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,705 | $134.59 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,702 | $119.37 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,821 | $115.28 |
| 84100 | <1% | 26 | $104.86 | |
| 84295 | <1% | 28 | $96.13 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 318 | $91.95 |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,658 | $81.57 |
| C1769 | Guide wire | <1% | 976 | $72.45 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,426 | $69.78 |
| 82272 | <1% | 16 | $51.55 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 963 | $47.91 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 538 | $43.70 |
| 82947 | <1% | 13 | $41.33 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,474 | $35.40 |
| 88304 | <1% | 137 | $32.93 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,146 | $31.21 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,318 | $26.30 |
| 72072 | <1% | 12 | $25.91 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,087 | $25.79 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,055 | $19.69 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 687 | $16.66 |
| J2704 | Injection, propofol, 10 mg | <1% | 10,895 | $16.51 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,574 | $14.26 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,953 | $10.78 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 244 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 1,979 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 2,021 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,572 | $0.00 |
| 51798 | 0% | 12 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 660 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 287 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 202 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 1,182 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 877 | $0.00 |
| 36000 | 0% | 290 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 359 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 508 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 347 | $0.00 |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 54 | $0.00 |
| J3590 | Unclassified biologics | 0% | 146 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 193 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 263 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 32 | $0.00 |
| J3490 | Unclassified drugs | 0% | 232 | $0.00 |
| A4364 | Adhesive, liquid or equal, any type, per oz | 0% | 13 | $0.00 |
| 80320 | 0% | 13 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 17 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 12 | $0.00 |
| C1778 | Lead, neurostimulator (implantable) | 0% | 12 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 35 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 19 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 17 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,453 | $0.00 |
| A4212 | Non-coring needle or stylet with or without catheter | 0% | 571 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 768 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 448 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 264 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 2,051 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,841 | $0.00 |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 20 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 469 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 226 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 298 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 40 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 184 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 998 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,148 | $0.00 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 155 | $0.00 |
| 76376 | 0% | 58 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 15 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 74 | $0.00 |
| A4565 | Slings | 0% | 39 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 17 | $0.00 |
| A6206 | Contact layer, sterile, 16 sq. in. or less, each dressing | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.